Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Elan Corporation recently initiated a phase II study on ELND005 (Study AG201) for the treatment of agitation/aggression in patients suffering from moderate-to-severe Alzheimer’s disease (AD).

The AG201 study will evaluate the efficacy, safety and tolerability of ELND005 for a period of 12 weeks in patients suffering from AD and experiencing at least moderate levels of agitation/aggression. Elan will enroll around 400 patients for the study in the US, Canada and other selected countries.

Elan stated in its press release that around 5.4 million people in the US and around 7.2 million people in the EU are suffering from AD. Almost 90% of AD patients develop neuropsychiatric symptoms (NPS) and around 60% of AD patients develop agitation/aggression. The company also stated that currently there are no approved therapies for agitation/aggression in the US and many other countries.

We note that companies like Pfizer, Inc. (PFE - Analyst Report), Eli Lilly and Company (LLY - Analyst Report) and Roche Holding (RHHBY - Analyst Report) are also looking to enter the Alzheimer’s disease market.

ELND005 is also being developed as an adjunctive maintenance treatment in patients suffering from bipolar I disorder (BPD 1) to lengthen the time period between mood episodes. In August this year, Elan initiated a phase II placebo-controlled, safety and efficacy study with oral ELND005 for this indication.

In 2006, Elan had entered into an exclusive, worldwide collaboration agreement with Transition Therapeutics, Inc. (TTHI) to jointly develop and commercialize ELND005.

Elan and Transition Therapeutics modified their agreement in 2010, following which Transition Therapeutics stopped funding the candidate’s development and commercialization and has given up its 30% ownership of the candidate to Elan. Elan paid Transition Therapeutics $9.0 million in January 2011. However, Elan will no longer be required to pay the previously stipulated $25 million as a milestone payment on the commencement of the phase III study of ELND005.

The company made a one-time clinical milestone payment of $11 million to Transition Therapeutics for the first patient dosing in the BPD 1 study.

Our Recommendation

We are pleased with the company’s progress with ELND005.  We expect investor focus to stay on the successful development of the candidate. We currently have a Neutral recommendation on Elan. The stock carries a Zacks #3 Rank (Hold rating) in the short run.

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GRP IN DXYN 15.84 +7.90%
BOFI HLDG IN BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%